Full Answer
See more
What diseases is Regeneron used for?
Our clinical portfolio currently includes antibody candidates for over 30 types of cancer, including cutaneous squamous cell carcinoma, basal cell carcinoma, non-small cell lung cancer, cervical, diffuse large B-cell lymphoma, follicular lymphoma, multiple myeloma, ovarian, prostate cancers and many more.
How do you request Regeneron?
To request infusion of monoclonal antibodies and a medical team at your facility, you may call the 24-hour State Infusion Hotline at 1- 800- 742- 5990. An Infusion Specialist will record your information and process your request.
How do I contact Regeneron?
Please call 1-844-REGN-MID (1-844-734-6643) for further information.
What type of company is Regeneron?
biotechnology companyRegeneron is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases.
How long does Regeneron infusion last?
If you are receiving an intravenous infusion, the infusion will take 20 to 50 minutes or longer. o After the initial dose, if your healthcare provider determines that you need to receive additional doses of REGEN-COV for ongoing protection, the additional intravenous or subcutaneous doses would be administered monthly.
Can monoclonal antibodies make Covid worse?
Some possible risks from antibody treatment are: It may interfere with your body's ability to fight off a future infection of COVID-19. It may reduce your body's immune response to a vaccine for COVID-19.
Where is Regeneron based?
Westchester County, New YorkRegeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York.
Where are Regeneron headquarters?
Tarrytown, NYRegeneron Pharmaceuticals / HeadquartersRegeneron Pharmaceuticals maintains its corporate office in Tarrytown, N.Y., as well as a manufacturing facility in Rensselaer, N.Y.
What is the Regeneron infusion for Covid?
The U.S. Food and Drug Administration (FDA) has granted an Emergency Use Authorization (EUA) for REGEN-COV® (casirivimab and imdevimab) for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of ...
Does Regeneron pay well?
Salaries at Regeneron Inc range from an average of $59,332 to $173,077 a year. Regeneron Inc employees with the job title Research Scientist make the most with an average annual salary of $101,422, while employees with the title Research Associate, Biotechnology make the least with an average annual salary of $73,273.
Is Regeneron a good company?
Regeneron Ranked #1 Biopharma Employer for Sixth Time by Science Magazine. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Science magazine has named the company the world's number one employer in its annual survey of the biotech and pharmaceutical industry.
Is Regeneron FDA approved?
Regeneron's bid for COVID-19 drug's full approval hits snag as FDA extends review.
When should I take Regeneron?
A. The EUA authorizes REGEN-COV to be administered as soon as possible after a positive viral test for COVID-19 and within 10 days of symptom onset. REGEN-COV is authorized for intravenous infusion, and intravenous infusion is strongly recommended.
What are the possible side effects of taking Regeneron to treat COVID-19?
after infusion or injection, including fever, difficulty breathing, rapid or slow heart rate, tiredness, weakness or confusion. If these symptoms occur, contact your healthcare provider or seek immediate medical attention as some of these symptoms have required hospitalization.
Does Regeneron help Covid?
Regeneron's infectious disease programs have led to an approved medicine for Ebola, an emergency use authorized medicine for COVID-19, and an investigational medicine for Middle East Respiratory Syndrome (MERS).
How is Regeneron administered?
About the REGEN-COV Antibody Cocktail REGEN-COV can be administered by IV infusion (as short as 20 minutes) or by SC injection (four injections), which is an alternative when IV infusion is not feasible and would lead to a delay in treatment.
What is Regeneron's belief?
We believe that patients should have access to appropriate, evidence-based medicines to get them to the best health. Patients are singularly able to tell their story about access challenges and how these obstacles can impact their daily lives and health. Regeneron has supported advocacy training, distribution of access tools, town halls and coalition building for patients and caregivers so that they can have a greater chance for successful outcomes. To submit a request for funding, visit our grants portal.
What is compassionate use policy?
Our Compassionate Use Policy gives certain patients who have serious or life-threatening conditions access to a potentially beneficial medicine when no comparable or satisfactory alternative therapy options or clinical trials area available. Compassionate Use, also known as expanded access in the U.S., is an approved pathway that, by design, is meant for exceptional circumstances. Our Compassionate Use program has certain established criteria and each request is reviewed by Regeneron’s Compassionate Use Committee.
What is patient advocacy?
We recognize that patient advocacy groups represent their respective patient communities’ needs, issues and challenges and can also help to raise awareness, empower patients through education and advocate for patients to receive the best care. We aim to develop meaningful, long-term relationships with patient advocacy groups and to collaborate on addressing important health issues that result in positive patient outcomes.
When was the Antibody Cocktail approved?
Data from this trial ultimately supported the U.S. Food and Drug Administration’s approval of our antibody cocktail on Oct. 14, 2020.
Is Regeneron a fast response?
To address emerging or rapidly spreading infectious diseases, Regeneron has applied our VelociSuite ® technologies in a ‘rapid response’ manner that parallel tracks certain steps and speeds hand-offs between groups in order to advance novel antibody treatments extremely quickly. We’ve been proud to apply our homegrown technologies and novel scientific approach to respond to public health challenges like Ebola, Middle East Respiratory Syndrome (MERS) and COVID-19.
Is manufacturing antibodies a process?
Manufacturing biologic medicines like antibodies is a time-consuming and precise process, and unfortunately biology can’t be hurried along. Despite the risks and uncertainties, we purposefully began this effort as early as possible so that we would have as many doses as possible immediately available for people around the world.